
Moderna's mRNA vaccine cuts skin cancer risk by nearly half in trial
The story in brief
Moderna's mRNA vaccine intismeran, when combined with pembrolizumab, almost halves the risk of skin cancer returning, according to leaked trial results. The phase III trial, involving 1,137 melanoma patients, will present findings at an October meeting. Moderna's stock dropped 25% after the leak.